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ABSTRACT
OBJECTIVE
To compare prevalent and incident morbidity and 
mortality between those with the HFE p.C282Y 
genetic variant (responsible for most hereditary 
haemochromatosis type 1) and those with no p.C282Y 
mutations, in a large UK community sample of 
European descent.
DESIGN
Cohort study.
SETTING
22 centres across England, Scotland, and Wales in UK 
Biobank (2006-10).
PARTICIPANTS
451 243 volunteers of European descent aged 40 
to 70 years, with a mean follow-up of seven years 
(maximum 9.4 years) through hospital inpatient 
diagnoses and death certification.
MAIN OUTCOME MEASURE
Odds ratios and Cox hazard ratios of disease 
rates between participants with and without 
the haemochromatosis mutations, adjusted for 
age, genotyping array type, and genetic principal 
components. The sexes were analysed separately as 
morbidity due to iron excess occurs later in women.
RESULTS
Of 2890 participants homozygous for p.C282Y (0.6%, 
or 1 in 156), haemochromatosis was diagnosed in 
21.7% (95% confidence interval 19.5% to 24.1%, 
281/1294) of men and 9.8% (8.4% to 11.2%, 
156/1596) of women by end of follow-up. p.C282Y 
homozygous men aged 40 to 70 had a higher 
prevalence of diagnosed haemochromatosis (odds 
ratio 411.1, 95% confidence interval 299.0 to 565.3, 
P<0.001), liver disease (4.30, 2.97 to 6.18, P<0.001), 
rheumatoid arthritis (2.23, 1.51 to 3.31, P<0.001), 
osteoarthritis (2.01, 1.71 to 2.36, P<0.001), and 
diabetes mellitus (1.53, 1.16 to 1.98, P=0.002), 
versus no p.C282Y mutations (n=175 539). During 
the seven year follow-up, 15.7% of homozygous men 
developed at least one incident associated condition 
versus 5.0% (P<0.001) with no p.C282Y mutations 
(women 10.1% v 3.4%, P<0.001). Haemochromatosis 
diagnoses were more common in p.C282Y/p.H63D 
heterozygotes, but excess morbidity was modest.
CONCLUSIONS
In a large community sample, HFE p.C282Y 
homozygosity was associated with substantial 
prevalent and incident clinically diagnosed morbidity 
in both men and women. As p.C282Y associated iron 
overload is preventable and treatable if intervention 
starts early, these findings justify re-examination of 
options for expanded early case ascertainment and 
screening.
Introduction
Hereditary haemochromatosis is an iron overload 
disease and is the most common genetic condition 
in people of European descent. Hereditary 
haemochromatosis type 1 is predominantly attributable 
to two HFE gene mutations, with 95% of affected 
people having the p.C282Y (p.Cyst282Tyr) mutation 
and 4% having the p.C282Y/p.Hist63Asp compound 
heterozygote genotype.1 The p.C282Y mutation 
alters a key amino acid, which in adults impairs HFE 
protein signalling and leads to reduced expression of 
hepcidin mRNA, decreased plasma hepcidin levels, 
and excessive systemic iron accumulation.2
The p.C282Y variant is present in 10-15% of 
populations of northern European descent, with 
approximately 1/150 people being homozygotes3 and 
the highest genotype prevalence reported in Ireland and 
Britain. In the USA, the prevalence of heterozygosity 
(C282Y/no p.C282Y mutations) in the third National 
Health and Nutrition Examination Survey (NHANES 
III)4 (n=5171) was 9.5% (95% confidence interval 
8.1% to 11.3%) in Non-Hispanic white people, with a 
lower prevalence in Non-Hispanic black people (2.3%, 
1.5% to 3.4%) and Mexican-Americans (2.8%, 1.9% to 
4.0%): 0.3% (0.1% to 0.8%) of studied Non-Hispanic 
white people were p.C282Y homozygote, with only one 
case each of p.C282Y homozygotes in the other two 
groups. Other HFE mutations linked to iron overload 
are present in other populations.
Hereditary haemochromatosis is characterised by 
accumulation of iron in parenchymal organs, and 
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The HFE p.C282Y homozygous mutation is the main cause of the iron overload 
disorder hereditary haemochromatosis (type 1) in populations of European 
descent
Iron overload is preventable and partly treatable by venesection, but diagnosis is 
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Community studies reported low penetrance, with one reporting that less than 
1% of p.C282Y homozygotes developed frank clinical haemochromatosis
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In women, 1 in 10 more developed morbidity
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clinical presentation classically includes liver cirrhosis, 
diabetes, and changes to skin colour, but diagnosis 
is now commonly triggered by chronic fatigue or 
arthropathy.5 Patients with haemochromatosis are 
susceptible to some infections,6 but the p.C282Y 
genotype is also associated with lower low density 
lipoprotein cholesterol levels.7
Studies of close relatives of patients with p.C282Y 
associated haemochromatosis suggested high 
penetrance to clinical disease: for example, Jacobs 
et al8 studied 735 first degree relatives of 224 
Dutch p.C282Y homozygotes with clinically overt 
haemochromatosis and found 45.7% of these family 
members had a haemochromatosis related diagnosis 
compared with 19.4% in general population controls. 
However, several studies in general populations have 
suggested much lower penetrance to clinical disease. 
The largest previous non-family based genetic study of 
haemochromatosis (HEIRS9) examined 62 749 women 
and 36 962 men (aged 25-100 years, median age 50 
years) from five North American clinical centres and 
included 299 HFE p.C282Y homozygotes. Genotype 
associations were tested with arthritis, diabetes, liver 
disease, heart disease, and impotence or infertility. 
The only association found was between p.C282Y 
homozygosity and “any liver disease” in men (odds 
ratio 3.28, 95% confidence interval 1.49 to 7.22 
compared with neither HFE variant), with liver 
disease present in 3.3% of the p.C282Y homozygote 
men studied. Similarly, Beutler et al10 studied 41 038 
people (n=152 p.C282Y homozygotes) attending a 
health appraisal clinic in the USA and concluded 
that less than 1% of p.C282Y homozygotes develop 
“frank clinical hemochromatosis.” However, clinical 
penetrance is best assessed on a lifetime, or at least 
later life, basis, and a recent review of four cohort 
studies of untreated p.C282Y homozygotes (total 107 
men and 129 women) suggested that 9% of male 
p.C282Y homozygotes eventually develop what the 
authors considered to be serious liver disease.11 Iron 
accumulates with advancing age, but data from large 
samples of older people who are homozygous for 
p.C282Y have been limited. Phlebotomy is effective at 
preventing iron overload and reducing or stabilising 
several but not all clinical outcomes,5 especially when 
started early. Case finding for haemochromatosis and 
HFE variants in close relatives is indicated, but general 
population screening is not recommended.12 13 This is 
partly because of the reported low clinical penetrance 
to liver disease and the absence of excess mortality in 
major studies.14
We estimated associations between HFE p.C282Y 
status and common conditions potentially linked 
to haemochromatosis in the large United Kingdom 
Biobank genotyped sample. We replicated the 
approaches previously used in studies of HFE 
mutations in larger general samples (mainly in HEIRS9 
and Beutler et al10), with some extensions. We tested 
genotype associations with conditions previously 
linked to HFE p.C282Y status or seen in people with 
haemochromatosis15—namely, haemochromatosis, 
liver disease (and liver cancer), diabetes mellitus, 
coronary artery disease and atrial fibrillation, 
arthrosis,16 arthritis (and hip replacements17), 
osteoporosis,18 tiredness,5 and susceptibility to 
infection6 assessed through occurrence of pneumonia. 
We used data on 451 243 UK Biobank community 
volunteers of European descent aged 40 to 70 years at 
baseline. We also examined associations with outcomes 
for the p.H63D HFE variant, plus the combined effect 
of three other small effect genetic variants influencing 
iron levels: rs855791 (nearest gene: TMPRSS6), 
rs7385804 (TFR2), and rs8177240 (TF).19
Methods
The UK Biobank study datasets include 502 634 
volunteers aged 40 to 70 years old (with small numbers 
to age 73), recruited through postal invitation to those 
who are registered with the UK National Health Service, 
living within 25 miles of 22 assessment centres in 
England, Scotland, and Wales. Baseline assessments 
(2006-10) included demographics, lifestyle, 
disease history, and physiological measurements.20 
Participants gave informed consent for genotyping 
and data linkage to medical records. The volunteers 
tended to be healthier at baseline than the general UK 
population.21
Genotyping and sample selection
Data were on 451 243 UK biobank participants of 
European descent with HFE p.C282Y (rs1800562) 
genotype information. We also investigated HFE 
p.H63D (rs1799945), as well as three iron related 
variants in other genes19 (rs855791, rs7385804, and 
rs8177240: see supplementary information).
Disease ascertainment
Ascertainment of prevalent disease was by participant 
responses to questionnaire items on doctor diagnosed 
diseases at baseline, and inpatient hospital records 
from 1996 to baseline interview according to ICD-
10 (international classification of diseases, 10th 
revision) codes (see supplementary table 1 and 
supplementary information). Diagnoses ascertained 
were haemochromatosis, liver conditions (any, based 
on ICD-10 codes), liver cancer (incident cases only), 
pneumonia, coronary artery disease (myocardial 
infarction or angina), atrial fibrillation, diabetes 
mellitus (predominantly type 2 but including type 1, 
as typing of diabetes in haemochromatosis might be 
unclear), osteoporosis, osteoarthritis, and rheumatoid 
arthritis. Numbers of p.C282Y homozygous 
participants with liver cancer (at baseline), diagnosed 
cardiomyopathy or heart failure, or reporting 
impotence or infertility, were too low to analyse. 
Participants self reported whether they were currently 
taking cholesterol lowering drugs and whether 
they had had a hip replacement; these were used in 
sensitivity analyses.
Self reported tiredness or lethargy in the previous 
two weeks at baseline in the UK Biobank study was 
reclassified from “not at all,” “several days,” “more 
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than half the days,” and “nearly every day,” combining 
the last two categories, compared with the rest. 
Participants responding “do not know” or “prefer 
not to answer” were excluded from analyses (<3% of 
responders).
Follow-up was in hospital inpatient data to March 
2016, national cancer registries (to September 2015), 
or death registration (February 2016): maximum 
follow-up was 9.4 years (mean 7 years). Analyses of 
each incident condition excluded those with each 
diagnosis at baseline.
Missing data
We excluded participants without imputed genotype 
data (n=15 233/502 642, 3.0%) and those with 
imprecise imputation for p.C282Y (n=183/487 409, 
0.04%). Less than 0.5% of participants had no 
recorded answers to questions on self reported 
disease diagnoses, cholesterol lowering drug use, 
hip replacement, or frequency of tiredness. Given the 
low level of missing data, we excluded participants 
with specific missing data from each analysis, as 
needed.
Statistical analysis
We sought to replicate the approaches previously 
used in studies of HFE mutations in larger general 
samples (mainly in HEIRS9 and Beutler et al10), with 
some extensions. Logistic regression tested baseline 
(cross sectional) genotype condition associations, 
with Cox proportional hazards regression models for 
all cause mortality and incident conditions. Models 
were adjusted for age, assessment centre, population 
substructure using the first five principal components 
of genetic variation generated in participants of 
European descent, and genotyping microarray 
(Affymetrix Axiom array 90% participants, Affymetrix 
BiLEVE array, sharing >95% content). In sensitivity 
analyses for models of incident diagnoses we used 
Fine and Gray competing risk models, with all cause 
mortality as the competing risk.22 All analyses were 
performed in Stata v14.1 with functions stcox and 
stcrreg for Cox proportional hazards regression models 
and competing risk models, respectively. Function 
prtest was used to test for significant differences 
in proportions. Figures were generated in R v3.4.1 
using packages metafor (v2.0) and ggplot2 (v2.2.1). 
An assumption of Cox’s proportional hazards (and 
competing risks) regression models is that the hazard 
ratio remains constant over time. The STATA function 
stphtest was used to test whether the proportional 
hazards assumption was violated in our models. We 
have followed the American Medical Association’s 
recommendation that P values <0.001 do not need to 
be specified (see the supplementary material for actual 
P values, often much lower).
We aimed to replicate the approaches previously 
used, but we did not register a specific analysis 
protocol before undertaking these analyses. Similarly 
the specific contents of measures of overall excess 
morbidity were not prespecified.
Multiple testing
Our study is essentially a replication of previous studies 
(especially HEIRS9 and Beutler et al10), examining 
associations between the two main HFE mutations 
and haemochromatosis associated morbidity. Our 
main analyses tested 11 key outcomes, all previously 
implicated in the single shared underlying process 
of iron overload—namely, haemochromatosis, 
cardiovascular disease, diabetes mellitus, any liver 
disease (with subanalyses of liver cancer), osteoarthritis, 
osteoporosis, rheumatoid arthritis, pneumonia, atrial 
fibrillation, tiredness, and death. We performed 
separate analyses for men and women, based on a 
priori evidence of later disease onsets in women. 
After the main analyses including the whole group 
aged 40 to 70, we provided age subgroup estimates, 
as iron accumulation progresses with advancing age. 
Extensive evidence exists for associations of the studied 
comparisons in people with haemochromatosis or with 
the p.C282Y genotype, so prior probabilities were not 
small, although unquantified in a comparable sample. 
We have reported and highlighted a main summary 
measure (ie, one or more of the core haemochromatosis 
associated diseases in all the studied men and women 
separately) as our overall main result. Given the 
context of this analysis, we report simple P values 
without correction for multiple testing, as we tested 
associations with raised prior probabilities. However, 
we also performed Benjamini-Hochberg multiple testing 
correction and report the effect on the main results.
Mendelian randomisation
To test the hypothesis that the HFE genotypes affect 
risk of incident disease by affecting iron levels, we 
utilised mendelian randomisation analysis methods. 
The mean transferrin saturation (%) (the most specific 
clinical measure of iron load) was used for each of 
the five HFE genotype groups (p.C282Y homozygotes, 
p.C282Y heterozygotes, p.C282Y/p.H63D compound 
heterozygotes, p.H63D alone, and those without either 
mutations), as reported by Allen et al.23 We used R 
(v3.5.1) package BSDA (v1.2.0) and function tsum.test 
to determine the difference in transferrin saturation 
between each genotype and the group with no p.C282Y 
mutations (see supplementary table 10). For each of 
the six main incident outcomes (haemochromatosis, 
liver disease, liver cancer, osteoarthritis, osteoporosis, 
and diabetes) we performed Cox’s proportional hazards 
regression models, using the same HFE genotype 
combinations as in Allen 2008 (see supplementary 
table 10). R package MendelianRandomisation (v0.3.0) 
tested whether the association between HFE genotype 
and incident outcomes could be caused by differences 
in transferrin saturation owing to genotype. The inverse 
variance weighted result was the primary method, and 
the weighted median and MR-Egger methods were used 
as sensitivity analysis to check for consistency and bias.
Patient and public involvement
Patients and participants were and are extensively 
involved in the UK Biobank study itself. We used 
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anonymised data that were already collected and 
therefore no patients were involved in setting the 
research question or the outcome measures. No 
patients were asked to advise on interpretation or 
writing up of results. UK Biobank notified participants 
of relevant health related findings in the baseline 
assessment, but there is no individual notification 
of subsequent findings, including in the genotyping. 
We do plan to disseminate the general results of the 
research to study participants and to the relevant 
patient community.
Results
Analyses included the 451 243 UK Biobank 
participants of European ancestry aged 40 to 70 
years at baseline, of whom 2890 were homozygous 
for p.C282Y (0.6%, or 1 in 156) and 64 444 (14.3%) 
heterozygous for p.C282Y: the remaining group with 
no p.C282Y mutations present, irrespective of p.H63D 
status, formed the key comparison group for the main 
analyses (n=383 909, 85.1%).
Haemochromatosis (hereditary not specified in the 
diagnostic data available) was diagnosed (table  1) 
at baseline in 7.3% (210/2890) of the p.C282Y 
homozygotes overall (versus 0.02% of those with no 
p.C282Y mutations), increasing to 15.1% (437/2890) 
by end of follow-up (versus 0.04% of those with no 
p.C282Y mutations). Rates of haemochromatosis 
diagnosis were higher in men: 156 of 1294 p.C282Y 
male homozygotes (12.1%, 95% confidence interval 
10.3% to 14.0%; table 1) at baseline, increasing to 281 
(21.7%, 19.5% to 24.1%) by end of follow-up. In 1596 
women, haemochromatosis diagnoses were present at 
baseline in 54 (3.4%, 2.6% to 4.4%), increasing to 156 
(9.8%, 8.4% to 11.2%) during follow-up.
Prevalent and incident diagnoses of 
haemochromatosis itself (irrespective of subtype) were 
also recorded for people with the p.C282Y heterozygote 
genotype, the p.H63D genotypes, and the p.C282Y/p.
H63D composite genotype, with 10.7% of diagnoses 
recorded in participants with none of the studied 
mutations (see supplementary table 2 for prevalent 
diagnoses, and supplementary table 4 for incident 
diagnoses).
p.C282Y homozygous status and prevalent 
conditions
Several associations with studied diagnoses were 
present in men (whole sample aged 40 to 70 years old 
at baseline, fig 1 and table 2; see supplementary table 
2 for full results). Male p.C282Y homozygotes had a 
higher prevalence of diagnosed haemochromatosis 
(odds ratio 411.1, 95% confidence interval 299.0 to 
565.3, P<0.001), as well as osteoarthritis (2.01, 1.71 
to 2.36, P<0.001), liver disease (4.30, 2.97 to 6.18, 
P<0.001), rheumatoid arthritis (2.23, 1.51 to 3.31, 
P<0.001), and diabetes mellitus (1.53, 1.16 to 1.98, 
P=0.002), compared with no p.C282Y mutations 
(n=175 539, irrespective of H63D status). Associations 
were also present for osteoporosis (2.23, 1.49 to 3.57, 
P<0.001) and pneumonia (1.62, 1.20 to 2.19, P=0.002). 
Contrary to these increases in morbidity, diagnoses of 
coronary artery disease were less common (0.76, 0.61 
to 0.95; P=0.016), although this association was no 
longer significant after correction for multiple testing 
(Benjamini-Hochberg corrected P=0.069): all other 
associations were still significant after multiple testing 
correction. No associations were found with tiredness 
or atrial fibrillations in men aged 40 to 70 years.
In women aged 40 to 70 years, p.C282Y 
homozygosity (n=1596, fig 1) was only associated with 
haemochromatosis (odds ratio 438.0, 95% confidence 
interval 247.9 to 773.9, P<0.001) and osteoarthritis 
(1.33, 1.15 to 1.53; P<0.001). Haemochromatosis 
was associated with p.C282Y homozygosity in all 
three 10 year age subgroups and in both sexes (see 
supplementary table 2). Most of the other conditions 
associated with p.C282Y homozygous status overall 
in men also reached statistical significance in the 50 
to 59 years and 60 to 70 years age subgroups (see 
supplementary fig 1), whereas the association with 
osteoarthritis was present in all three age groups. 
Frequent tiredness or lethargy was associated with 
p.C282Y homozygosity in men aged 60 to 70 only 
(1.43, 1.10 to 1.84; P=0.007). In women, none of the 
age specific analyses reached significance.
We repeated prevalent analyses including an 
interaction term between p.C282Y genotype and sex, 
to test whether the difference seen between men and 
Table 1 | Characteristics of sample, stratified by p.C282Y genotype (homozygotes, heterozygotes, and no p.C282Y mutations, sex and age
Characteristics
Men Women
Homozygotes Heterozygotes No p.C282Y mutations* Homozygotes Heterozygotes No p.C282Y mutations*
All ages (40-70 years):
 No (%) 1294 (0.6) 29 536 (14.3) 175 539 (85.1) 1596 (0.65) 34 908 (14.3) 208 370 (85.1)
 Mean (SD) age (years) 56.85 (8.18) 57.01 (8.12) 57.00 (8.11) 56.94 (7.98) 56.48 (7.97) 56.61 (7.94)
 No (%) consuming alcohol daily† 324 (25.1) 7544 (25.6) 46 342 (26.4) 256 (16.0) 5765 (16.5) 35 191 (16.90)
  No (%) with haemochromatosis 
baseline diagnosis 156 (12.1) 56 (0.2) 55 (0.03) 54 (3.4) 17 (0.05) 16 (0.01)
Older ages (60-70 years):
 No (%) 593 (0.6) 13 599 (14.3) 80 945 (85.1) 719 (0.7) 14 905 (14.1) 90 214 (85.2)
 Mean (SD) age (years) 64.19 (2.84) 64.29 (2.85) 64.25 (2.86) 64.26 (2.82) 64.02 (2.86) 64.04 (2.84)
 No (%) consuming alcohol daily† 173 (29.2) 3962 (29.2) 24 277 (30.0) 125 (17.4) 2696 (18.1) 16 714 (18.5)
 No (%) with haemochromatosis 
baseline diagnosis 81 (13.7) 31 (0.2) 35 (0.04) 34 (4.7) 7 (0.05) 5 (0.01)
*No p.C282Y mutations, irrespective of p.H63D status.
†0.07% of participants with missing data were excluded.
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women was statistically significant. Sex significantly 
interacted with p.C282Y for prevalent osteoporosis 
(P=0.004 for interaction), osteoarthritis (P<0.001 
for interaction), rheumatoid arthritis (P<0.001 for 
interaction), pneumonia (P=0.01 for interaction), and 
liver disease (P=0.001 for interaction). In all cases, 
being male increased the association.
p.C282Y homozygous status associations with 
incident conditions
During follow-up (mean 7 (maximum 9.4) years), 107 
p.C282Y homozygous participants died (hazard ratio 
1.23, 95% confidence interval 1.01 to 1.48, P=0.04 
compared with 11 092 deaths in participants with no 
p.C282Y mutations; see supplementary fig 2). Age 
group and sex specific associations with mortality did 
not reach significance, and the overall association with 
mortality was no longer significant after adjustment 
for multiple testing (Benjamini-Hochberg P=0.36; see 
supplementary table 3). Also see post hoc analyses of 
cause of death in the section on sensitivity analyses.
In men aged 40-70 years without a haemochromatosis 
diagnosis at baseline, p.C282Y homozygotes were 
more likely to have a diagnosis of haemochromatosis 
during follow-up compared with participants with 
no p.C282Y mutations (hazard ratio 286.2, 95% 
confidence interval 211.0 to 388.0). The p.C282Y 
homozygous women also had an increased likelihood 
of receiving a diagnosis of haemochromatosis (427.3, 
285.4 to 639.7). Overall, male p.C282Y homozygotes 
were more likely to have a diagnosis during follow-
up than female p.C282Y homozygotes (1.73, 1.33 to 
2.25, P<0.001). Numbers of incident diagnoses in 
the p.C282Y homozygote group were relatively low 
(see supplementary table 4) but p.C282Y homozygote 
males aged 40 to 70 had a higher incidence of any 
liver disease (2.35, 1.60 to 3.43, P<0.001), as well as 
incident liver cancer (n=11 in p.C282Y homozygote 
males, hazard ratio 8.88, 95% confidence interval 
4.79 to 16.45, P<0.001). Associations were also found 
with incident osteoarthritis in both men and women 
aged 40 to 70 (1.84, 1.20 to 2.80, P=0.005, and 1.81, 
1.26 to 2.60, P=0.001, respectively) and with incident 
osteoporosis in the male p.C282Y homozygotes 
(2.18, 1.13 to 4.21, P=0.021), although this last 
association was no longer significant after correction 
for multiple testing (Benjamini-Hochberg P=0.14). We 
repeated analyses of incident diagnoses including an 
interaction term between sex and p.C282Y genotype: 
only liver cancer (P=0.038 for interaction) and liver 
disease (P=0.049 for interaction) interaction terms 
were statistically significant, with male sex increasing 
the estimated effect size.
As iron overload in haemochromatosis affects many 
parenchymal tissues, we also calculated a summary 
Men
  Liver disease (any)
  Osteoporosis
  Rheumatoid arthritis
  Osteoarthritis
  Pneumonia
  Diabetes (type 1 or 2)
  Atrial fibrillation
  Coronary artery disease
  Frequent tiredness
Women
  Liver disease (any)
  Osteoporosis
  Rheumatoid arthritis
  Osteoarthritis
  Pneumonia
  Diabetes (type 1 or 2)
  Atrial fibrillation
  Coronary artery disease
  Frequent tiredness
4.30 (2.99 to 6.18)
2.30 (1.49 to 3.57)
2.23 (1.51 to 3.30)
2.01 (1.71 to 2.36)
1.62 (1.20 to 2.19)
1.52 (1.18 to 1.98)
0.88 (0.60 to 1.29)
0.76 (0.60 to 0.95)
1.16 (0.98 to 1.38)
1.26 (0.65 to 2.44)
1.09 (0.84 to 1.43)
0.81 (0.53 to 1.23)
1.33 (1.15 to 1.53)
0.86 (0.57 to 1.29)
1.18 (0.83 to 1.69)
0.90 (0.52 to 1.57)
0.86 (0.64 to 1.15)
1.06 (0.91 to 1.22)
0.5 2 841
Conditions Odds ratio
(95% CI)
Odds ratio
(95% CI)
Fig 1 | Prevalent conditions in studied sample (aged 40-70 at baseline): Forest plot 
of associations comparing p.C282Y homozygous status with no p.C282Y mutations, 
irrespective of p.H63D status, in men and women. Odds ratios are from logistic 
regression models adjusted for age, genotyping array type, and genetic principal 
components. See supplementary table 2 for details
Table 2 | Prevalence of p.C282Y associated baseline conditions by genotype (homozygotes, heterozygotes, and no pC282Y mutations, in participants 
aged 40-70 years. Values are numbers (percentages)
Baseline conditions
Men Women
Homozygotes Heterozygotes No p.C282Y mutations* Homozygotes Heterozygotes No p.C282Y mutations*
Haemochromatosis 156 (12.1) 56 (0.2) 55 (0.03) 54 (3.4) 17 (0.05) 16 (0.01)
Atrial fibrillation 27 (2.1) 769 (2.6) 4166 (2.4) 13 (0.8) 307 (0.9) 1751 (0.8)
CAD (myocardial infarction or angina) 84 (6.5) 2434 (8.2) 14 341 (8.2) 47 (2.9) 1141 (3.3) 6495 (3.1)
Diabetes (type 1 or 2) 61 (4.7) 1000 (3.4) 5523 (3.15) 31 (1.9) 568 (1.6) 3371 (1.6)
Liver disease 31 (2.4) 178 (0.6) 910 (0.5) 9 (0.6) 149 (0.4) 864 (0.4)
Osteoarthritis 182 (14.1) 2268 (7.7) 13 105 (7.5) 227 (14.2) 3780 (10.8) 22 522 (10.8)
Osteoporosis 21 (1.6) 206 (0.7) 1164 (0.7) 57 (3.57) 1042 (2.98) 6305 (3.03)
Pneumonia 45 (3.5) 654 (2.2) 3844 (2.2) 24 (1.5) 634 (1.8) 3626 (1.7)
Rheumatoid arthritis 26 (2.0) 249 (0.8) 1552 (0.9) 22 (1.4) 533 (1.5) 3399 (1.6)
Tiredness 68 (11.9) 1085 (8.3) 6455 (8.3) 76 (11.4) 1365 (9.65) 8630 (10.1)
≥1 core haemochromatosis diagnosis† 346 (26.7) 3518 (11.9) 19 778 (11.3) 304 (19.05) 4743 (13.6) 28 487 (13.7)
≥1 condition (any) 421 (32.5) 4922 (16.7) 28 143 (16.0) 398 (24.9) 6888 (19.7) 41 531 (19.9)
CAD=coronary artery disease.
*No p.C282Y mutations, irrespective of p.H63D status.
†Includes haemochromatosis; diabetes, liver disease, including liver cancer; osteoarthritis; and rheumatoid arthritis. Any associated condition also includes osteoporosis, pneumonia, and 
tiredness.
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measure of excess incident morbidity, to allow 
estimation of overall absolute differences in morbidity. 
We estimated incidence of the core diagnoses linked to 
haemochromatosis—namely, haemochromatosis itself, 
any liver disease (including liver cancer), diabetes, 
osteoarthritis, or rheumatoid arthritis. During the seven 
year mean follow-up, 15.7% of the p.C282Y homozygote 
men (all ages) developed at least one “core” condition 
(after excluding prevalent cases) compared with 5.0% 
of men with no p.C282Y mutations (10.7 percentage 
point difference, 95% confidence interval 8.4 to 13.4; 
P<0.001); in women the respective estimates were 
10.1% versus 3.4% (6.7 percentage point difference, 
5.0 to 8.3; P<0.001, see supplementary table 5). 
These absolute estimates increase with age (fig 2, see 
supplementary table 5). In time-to-event analysis, both 
male and female p.C282Y homozygotes had higher 
hazards for incident morbidity (men: hazard ratio 3.37, 
95% confidence interval 2.87 to 3.97, P<0.001; women 
2.99, 2.51 to 3.55, P<0.001; fig 3; see supplementary 
figs 3 and 4). Sensitivity analyses combining the above 
diagnoses (haemochromatosis, any liver disease, 
liver cancer, diabetes, osteoarthritis, and rheumatoid 
arthritis) with osteoporosis and pneumonia gave 
slightly higher estimates: 19.3% of p.C282Y male 
homozygotes aged 40-70 years developed at least one 
condition during follow-up (after excluding prevalent 
cases) compared with 8.7% of participants with no 
p.C282Y mutations (10.6% difference, 95% confidence 
interval 13.2% to 8.1%, P<0.001). In women, the 
respective estimates were 12.4% versus 6.2% (6.2% 
difference, 8.0% to 4.4%, P<0.001).
Overall penetrance in p.C282Y homozygotes
Overall penetrance (ie, having at least one diagnosis 
of haemochromatosis; any liver disease, including 
liver cancer; diabetes; osteoarthritis; or rheumatoid 
arthritis, including prevalent and incident diagnoses 
at end of follow-up, mean age 63.8 years) was 38.3% 
in p.C282Y homozygous men (all ages) compared with 
15.7% in men with no p.C282Y mutations—that is, 
an additional 22.6% of male p.C282Y homozygotes 
developed one or more of these diagnoses (95% 
confidence interval 19.9% to 25.2%, P<0.001, with the 
highest absolute rates in the older groups. In women, 
the respective estimates were 27.2% (25.0% to 29.4%) 
versus 16.6% (16.6% to 16.8%), excess morbidity 
10.6% (8.4% to 12.8%, P<0.001) (see supplementary 
fig 5 and supplementary table 5).
Incident morbidity in p.C282Y/p.H63D compound 
heterozygotes
Of the 451 243 participants, 10 701 (2.4%) were 
p.C282Y/p.H63D compound heterozygotes (4955 
were men, 46.3%). Mortality was not increased in 
p.C282Y/p.H63D compound heterozygotes (P=0.31) 
compared with participants with neither p.C282Y nor 
p.H63D mutations.
After excluding 79 participants with a prevalent 
diagnosis of haemochromatosis, compound 
heterozygotes had an increased likelihood of incident 
haemochromatosis diagnoses (men n=46, compound 
heterozygote cases, hazard ratio 33.63, 95% confidence 
interval 21.44 to 52.76, P<0.001; women n=17, 34.74, 
16.47 to 73.29, P<0.001) compared with participants 
with neither p.C282Y nor p.H63D mutations 
(n=268 577, of which 122 841 were men, 45.7%).
The compound heterozygous participants were also 
more likely to have at least one incident diagnosis of 
haemochromatosis; any liver disease, including liver 
cancer; diabetes; osteoarthritis; or rheumatoid arthritis 
(men: hazard ratio 1.17, 95% confidence interval 1.03 
to 1.33, P=0.016; women: 1.18, 1.03 to 1.37, P=0.022; 
fig 3; see supplementary table 4 for details), although 
these associations were no longer significant after 
correction for multiple testing (Benjamini-Hochberg 
P=0.14 and 0.14, respectively).
Incident morbidity in p.C282Y heterozygotes
Overall, 64 444 participants were heterozygous for 
p.C282Y (irrespective of p.H63D status, 14.3%), of 
whom 29 526 were men (45.8% of 64 444). Mortality 
was not increased in p.C282Y heterozygotes (P>0.05) 
compared with participants with no p.C282Y 
mutations. After excluding participants with prevalent 
haemochromatosis, the p.C282Y heterozygotes had 
an increased likelihood of a haemochromatosis 
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Fig 2 | Percentage of participants with at least one incident diagnosis during follow-up, 
by age group, sex, and p.C282Y genotype. Absolute percentages and 95% confidence 
intervals are shown. Diagnoses included haemochromatosis, any liver disease, 
liver cancer, diabetes, osteoarthritis, and rheumatoid arthritis. Prevalent cases are 
excluded. All comparisons are with no p.C282Y mutations, irrespective of p.H63D 
status. See supplementary table 5 for details
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diagnosis (men: hazard ratio 5.77, 95% confidence 
interval 4.09 to 8.13, P<0.001; women: 5.30, 3.201 to 
8.78, P<0.001) compared with no p.C282Y mutations 
(n=383 909 (45.72%) of whom 175 539 were men).
After excluding 10 660 p.C282Y/p.H63D compound 
heterozygotes, simple p.C282Y heterozygotes only 
were still more likely to have a diagnosis of incident 
haemochromatosis (3.42, 2.17 to 5.38, P<0.001) 
compared with those with no p.C282Y or p.H63D 
mutations. We observed no excess morbidity (at 
least one diagnosis of incident haemochromatosis; 
any liver disease, including liver cancer; diabetes; 
osteoarthritis; or rheumatoid arthritis) in the p.C282Y 
heterozygous men (P=0.78) and a nominally increased 
likelihood in the p.C282Y heterozygous women (1.08, 
1.01 to 1.15, P=0.023) compared with those with no 
p.C282Y mutations (fig 3). After excluding 10 660 
p.C282Y/p.H63D compound heterozygotes, p.C282Y 
heterozygous women no longer had an increased 
risk of incident excess morbidity (1.07, 0.99 to 1.15, 
P=0.07) compared with women with no p.C282Y or 
p.H63D mutations.
Interactions with small effect iron variants
We tested for interactions between p.C282Y and 
a single genetic risk score for increased iron 
levels in men aged 40-70 (combining three alleles 
associated with iron levels,19 weighted for effect size, 
excluding p.C282Y and p.H63D: see supplementary 
information). We found no significant (P>0.05) 
interactions for the prevalent or incident diseases 
individually (see supplementary table 6). However, 
for incident excess morbidity (at least one diagnosis 
of haemochromatosis; any liver disease, including 
liver cancer; diabetes; osteoarthritis; or rheumatoid 
arthritis) a statistical interaction between p.C282Y 
homozygosity and the iron single genetic risk score 
(P=0.001, Benjamini-Hochberg P=0.018) was present. 
In further investigations, p.C282Y homozygous 
men above the mean iron single genetic risk score 
had a 51% increased risk of an incident diagnosis 
(of haemochromatosis; any liver disease, including 
liver cancer; diabetes; osteoarthritis; or rheumatoid 
arthritis; hazard ratio 1.51, 95% confidence interval 
1.09 to 2.09, P=0.01) compared with p.C282Y 
homozygotes below the mean iron single genetic risk 
score.
Sensitivity analyses
Given the associations of p.C282Y homozygosity with 
lower prevalence of coronary artery disease in men 
aged 40 to 70 at baseline, we tested associations with 
self reported use of cholesterol lowering drugs (47 141 
of 206 175 men (22.9%)). p.C282Y homozygous 
men (aged 40 to 70) had a reduced likelihood of 
using cholesterol lowering drugs at baseline (odds 
ratio 0.76, 95% confidence interval 0.68 to 0.85; 
P<0.001) compared with men with no p.C282Y 
mutations. p.C282Y homozygous women (aged 40-
70) also reported less use of cholesterol lowering 
drugs (0.75, 0.67 to 0.84; P<0.001), although the 
p.C282Y association with coronary artery disease 
was not significant in this group (P>0.05). We also 
repeated the analyses of the significant associations 
of p.C282Y with prevalent and incident diagnoses 
excluding participants self reporting use of cholesterol 
lowering drugs. All associations remained significant, 
with consistent or greater effect estimates (except for 
prevalent coronary artery disease, which became non-
significant after removing the treated cardiovascular 
disease risk group: P=0.8) (see supplementary table 
7 for full results). Given the p.C282Y homozygote 
associations with arthritis and osteoporosis, we 
undertook additional analyses on self reported 
receipt of hip replacement at baseline (to provide 
a hard endpoint): both male and female p.C282Y 
homozygotes had higher rates of hip replacement 
(2.62, 1.97 to 3.49, P<0.001 and 1.90, 1.52 to 2.54, 
P<0.001, respectively) compared with participants 
with no p.C282Y mutations.
Given the nominally significant p.C282Y homozygote 
association with excess mortality (when combining 
men and women, aged 40 to 70 at baseline) during 
follow-up, we undertook post hoc analyses on causes 
of death. The doctor recorded primary cause for 14 of 
these deaths was liver cancer (hepatic cell carcinoma 
n=10, intrahepatic bile duct carcinoma n=4), and 
12 of these liver cancers occurred in male p.C282Y 
homozygotes. The odds ratio for p.C282Y homozygotes 
for liver cancer as a cause of death was 8.40 (95% 
confidence interval 4.68 to 15.05, P<0.001) compared 
with no p.C282Y mutations: men 14.01 (7.20 to 27.28, 
P<0.001); not significant in females P=0.26. No other 
main underlying causes of death were recorded in 
more than 10 of the p.C282Y homozygous participants 
who died.
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Fig 3 | Forest plot of associations for developing at least one p.C282Y associated 
incident condition (incident haemochromatosis, liver disease (including liver cancer), 
diabetes (type 1 or 2), rheumatoid arthritis, or osteoarthritis) by end of follow-
up, stratified by genotype and sex. Hazard ratios are from time-to-event (Cox’s 
proportional hazards regression) models adjusted for age, genotyping array type, 
and genetic principal components. The homozygous and heterozygous (p.C282Y/p.
C282Y and p.C282Y/−, respectively) groups are compared with participants with no 
p.C282Y mutations, irrespective of p.H63D status. The p.C282Y/p.H63D group are 
compared with participants without p.C282Y and p.H63D mutations. p.H63D/p.H63D 
and p.H63D/− groups are compared with participants with no p.H63D mutations. See 
supplementary table 4 for details
 o
n
 28 January 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k5222 on 16 January 2019. Downloaded from 
RESEARCH
8 doi: 10.1136/bmj.k5222 | BMJ 2019;364:k5222 | the bmj
The UK Biobank sample studied included 27 573 
pairs of first degree relatives (KING kinship coefficient 
>0.177). To avoid inflation of associations from 
family effects, we excluded one randomly selected 
participant from each pair related to the third degree 
(kinship coefficient >0.0442) or closer (n=71 651), 
leaving 379 592 unrelated participants for sensitivity 
analyses. The results were similar to the main results 
(see supplementary table 8): the proportion of male 
p.C282Y homozygotes aged 40 to 70 with at least one 
positively associated diagnosis (haemochromatosis; 
any liver disease, including liver cancer; diabetes; 
rheumatoid arthritis; or osteoarthritis) was 14.6%, 
compared with 5.0% in those with no p.C282Y 
mutations (absolute excess 9.58 percentage points, 
95% confidence interval 7.12 to 12.05): the 
comparative results for the overall sample were 15.7% 
and 5.0%, respectively, suggesting that inclusion or 
exclusion has little effect on estimates.
We tested for multiplicative risk effects (statistical 
interaction terms) between p.C282Y homozygous 
status and daily alcohol consumption in men aged 
40 to 70 for each baseline associated condition, plus 
the combined measure of morbidity: no interactions 
were significant (P>0.05), implying that daily alcohol 
intake seems to be an additive risk factor for studied 
outcomes. In further analyses, 88.4% of men aged 
40-70 self reported weekly alcohol intake, and those 
in the top 20% of alcohol intake consumed more than 
37.2 units (1 unit=10 mL) each week. In men with no 
p.C282Y mutations, being in the top 20% of alcohol 
intake was associated with an increased risk of incident 
liver disease (hazard ratio 1.75, 95% confidence 
interval 1.55 to 1.96, P<0.001) compared with being in 
the other alcohol intake groups (excluding those with 
missing data). Similarly, male p.C282Y homozygotes in 
the top 20% of alcohol intake also had raised hazards 
for incident liver disease (2.49, 1.02 to 6.06, P=0.04), 
but confidence intervals were wide and overlapped 
with the previous estimate.
We repeated the primary analyses of incident 
diagnoses using competing risks regression models, 
with all cause mortality as the competing risk.22 
We found that including mortality as a competing 
risk altered the associations only slightly (see 
supplementary table 9), suggesting that the primary 
results presented from Cox’s proportional hazards 
regression models are reliable and not biased by 
including participants who died in the censored group.
We investigated whether the HFE p.C282Y 
associations with specific diseases could be due to 
statistical co-localisation with other genetic variants 
in the region (see supplementary methods). No 
strong evidence supported a likely causal role for 
other variants, although five of the seven potential 
candidates were not directly genotyped, so further 
work may be justified (see supplementary results).
As measures of transferrin saturation were not 
available, we modelled transferrin saturation related 
genetic variant associations with diagnoses using 
mendelian randomisation approaches (supplementary 
tables 10 and 11). In men, increased genetically 
instrumented transferrin saturation (reported by Allen 
et al23) was associated with incident haemochromatosis 
(inverse variance weighted β=0.15, P<0.001), liver 
disease (β=0.016, P=0.005), liver cancer (β=0.047, 
P<0.001), osteoarthritis (β=0.012, P=0.005), 
osteoporosis (β=0.015, P=0.02), but not diabetes 
(type 1 or 2: β=0.006, P=0.06). In women, increased 
genetically instrumented transferrin saturation was 
associated with incident haemochromatosis (β=0.25, 
P<0.001) and osteoarthritis (β=0.015, P=0.002). The 
associations were consistent in the sensitivity analyses. 
Full results are available in supplementary table 11, 
and supplementary figures 8-14 show the individual 
HFE genotypes plotted against incident disease risk. 
Caution is needed in interpreting these results as the 
methods might not apply to the extreme transferrin 
saturation levels seen in HFE genotypes (eg, Allen 
et al23 reported a mean transferrin saturation of 73% 
in male p.C282Y homozygotes compared with 30% in 
males with no p.C282Y mutations; that is, more than 
40 standard deviations above the mean for the wild 
type genotype).
Finally, to further explore relevance to daily clinical 
practice in the UK, we estimated the proportions of 
cases of each condition that occurred in p.C282Y 
homozygous men and women. In men, 1.59% of all hip 
replacements at baseline were in p.C282Y homozygotes. 
During follow-up 5.82% of all incident liver cancers 
in the studied UK Biobank sample occurred in the 
p.C282Y homozygotes (see supplementary table 4), 
1.45% of incident liver diseases, 1.40% of incident 
osteoporosis, 1.12% of incident osteoarthritis, 
0.89% of incident diabetes (type 1 or 2), 0.86% of 
incident rheumatoid arthritis, and 0.67% of incident 
pneumonia in the studied UK Biobank sample occurred 
in male p.C282Y homozygotes.
Discussion
Previous evidence suggested that penetrance to disease 
in the highest risk hereditary haemochromatosis HFE 
p.C282Y homozygote family members was common, 
but penetrance in community samples was reportedly 
low. We studied a large UK based community volunteer 
sample aged 40 to 70 at baseline, with a mean seven 
year follow-up. p.C282Y homozygous men aged 40 
to 70 had substantial excess morbidity at baseline 
across several body systems typically affected in 
haemochromatosis, with increased prevalence of 
haemochromatosis itself, diabetes, rheumatoid 
arthritis, osteoarthritis, and liver disease compared 
with people with no p.C282Y mutations. In prospective 
analyses during follow-up, p.C282Y homozygous 
status was also associated with substantial incident 
morbidity in both men and women: 15.7% of the men 
developed at least one incident haemochromatosis, 
diabetes, arthritis, or liver disease compared with 5.0% 
in men with no p.C282Y mutations, with the respective 
estimates for women being 10.1% and 3.4%. These 
incidence rates alone indicate penetrance to diagnosed 
disease in p.C282Y homozygotes was not uncommon 
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in our community sample. We also found a nominally 
significant increase in mortality in the p.C282Y 
homozygotes overall (despite reduced prevalence of 
coronary artery disease in men), although numbers 
of deaths were small. Excess morbidity with the other 
studied genotypes (p.C282Y heterozygote, p.C282Y/p.
H63D composite genotype) was modest, although 
these genotypes were associated with excess diagnoses 
of haemochromatosis.
Limitations and comparisons with previous studies
Although the UK Biobank is a volunteer sample, our 
observed prevalence of p.C282Y heterozygote status 
(14.3% in UK Biobank) is similar to the 14.1% in 
a group of predominantly British or Irish descent 
in Australia.24 Our results are broadly consistent 
with those of Asberg et al,25 who studied transferrin 
saturation levels in 65 238 Norwegians (mean age 
49 years) in a population based health survey and 
found p.C282Y homozygous status in 171 men 
(population prevalence 0.68%) and 126 women 
(prevalence 0.41%) with serological evidence of iron 
overload. Overall, 57% of these men and 52% of 
these p.C282Y homozygote women had raised alanine 
aminotransferase concentrations (suggesting liver 
involvement), plus fatigue, joint pain, impotence 
(men), or diabetes mellitus, with joint pain alone being 
present in 20.3% of the men and 13.0% of the women. 
Other large sample population representative data on 
p.C282Y health outcomes are limited, with the largest 
study (HEIRS9) examining genotypes in 99 711 North 
American participants from primary care practices 
and blood sampling laboratories (median age 50, 
n=299 p.C282Y homozygotes). HEIRS found only an 
association between p.C282Y homozygous status and 
any liver disease in men. Beutler et al9 studied 41 038 
individuals who had chosen to attend health appraisal 
clinics offered by Kaiser Permanente in California, 
with the 152 p.C282Y homozygotes having only excess 
“liver trouble” or hepatitis, and the authors concluded 
a “best estimate” that less than 1% of homozygotes 
develop “frank clinical haemochromatosis.” Even the 
largest previous studies contained relatively small 
numbers of p.C282Y homozygote individuals compared 
with UK Biobank (n=2890 versus HEIRS9 n=299, 
Kaiser Permanente n=152), limiting their statistical 
power to detect excess diagnoses: for example, Beutler 
et al10 had only 19% power at P=0.05 to detect our 
p.C282Y male homozygote association with diabetes 
(odds ratio 1.44 in UK Biobank) in their sample of 56 
p.C282Y homozygous men. In the UK Biobank analysis 
of incident diabetes, we had 80% power to detect an 
odds ratio of 1.034 in our sample of 1281 p.C282Y 
homozygous men compared with 174 760 controls 
compared to controls with no p.C282Y mutations 
(n=6358 incident cases versus 169 683 controls), with 
P<0.05.
Many smaller studies26 examined p.C282Y 
associations using varying methodology and with 
varying results, with overall clinical penetrance being 
low in the predominantly p.C282Y heterozygotes 
studied. We also found a low incidence of 
haemochromatosis associated diagnoses with p.C282Y 
heterozygote status alone (compared with no p.C282Y 
mutations, excluding p.C282Y homozygotes). We did 
find one modest association between the compound 
heterozygous p.C282Y/p.H63D genotype and excess 
incident morbidity in men aged 40 to 49. More work is 
needed to establish whether this association replicates 
in other populations and whether interacting 
factors increase the risk of disease in this and the 
other genotypes. Our results included a nominally 
significant association with mortality in the combined 
male and female p.C282Y homozygote group, although 
this was based on only 107 deaths: previous studies 
have reported increased mortality in patients with 
hereditary haemochromatosis and liver disease, 
but not otherwise.27 28 Liver cancer was recorded 
on the death certificates of 14 of the 107 p.C282Y 
homozygous decedents in our study. In analyses of 
specific incident diagnoses we have accounted for this 
differential mortality using competing risks analyses in 
a sensitivity analysis: this made little difference to the 
results, likely because of the relatively small numbers 
of deaths.
One beneficial aspect of p.C282Y homozygous 
status is our finding that prevalence of coronary artery 
disease was reduced in men, as was use of cholesterol 
lowering drugs in both men and women aged 40-
70. This is consistent with the lower low density 
lipoprotein cholesterol levels previously reported7 
28 in p.C282Y homozygotes. Miller and Hutchins29 
found a reduced prevalence of coronary artery disease 
in patients with haemochromatosis. In a mendelian 
randomisation analysis, Gill et al30 recently found 
that higher genetically determined iron levels were 
associated with reduced risk of coronary artery disease 
(although separate data on HFE p.C282Y homozygotes 
were not modelled). Further application of mendelian 
randomisation analysis could help clarify the 
contribution of iron levels to other studied morbidities.
Other limitations of our analyses include that UK 
Biobank volunteers tended to be healthier than the 
general population21 at baseline. Also, it is possible that 
response rates to UK biobank may have been affected 
by HFE mutation status or associated morbidity. As 
noted, the overall prevalence of p.C282Y homozygosity 
(1 in 156) was similar to previous reports for groups of 
British or Irish descent, and the p.C282Y variant was in 
Hardy-Weinberg equilibrium (P>0.05) in UK Biobank, 
implying that the observed genotypes are present in the 
expected proportions, with no sign of differential loss 
or excess of p.C282Y homozygotes. More importantly, 
we found high rates of incident haemochromatosis 
associated diagnoses with p.C282Y homozygosity 
during the follow-up period, after excluding people 
with prevalent diagnoses at baseline. The UK Biobank 
sample included a wide range of exposures and 
socioeconomically diverse groups,21 and prospective 
analyses are much less affected by sample response 
patterns at baseline. These factors and the similarity 
of our findings to the Norwegian population sample by 
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Asberg et al25 suggest that our results are robust and 
likely to be applicable to the UK population and other 
populations of European descent.
The UK Biobank sample included some sets of 
related people, as assessed through genome wide 
variant similarity (KING kinship coefficient). In our 
incident estimates, we excluded those with existing 
haemochromatosis diagnoses at baseline and found 
that results were similar whether we included or 
excluded up to third degree relatives (see sensitivity 
analyses and supplementary table 6). However, 
UK Biobank lacks data on whether each related 
or unrelated UK Biobank participant was from a 
family with a strong history of haemochromatosis 
diagnoses.
For incident diagnoses, we used competing risk 
regression models accounting for the competing risk of 
mortality in sensitivity analyses, as many people only 
receive a diagnosis of haemochromatosis at older ages, 
when background mortality is substantial (see for 
example the eMERGE31 clinical biobank study across 
seven North American medical centres), although 
estimates using simple Cox regression yielded similar 
results (see supplementary information). We used 
proportional hazards regression models for incidence 
estimates, which assume that hazards do not vary over 
time. Tests of this assumption were negative for all 
outcomes tested, with one exception: diabetes in men, 
which showed few cases in the p.C282Y homozygotes 
during the first two years (see supplementary 
information). After excluding the first two years of 
data, the association between p.C282Y homozygosity 
and incident diabetes no longer had a significant 
violation of the proportional hazards assumption. 
Overall therefore we found no evidence of excess 
morbidity in p.C282Y homozygotes in the early years 
of follow-up, as might happen if these people were 
more likely to take part in this volunteer genetics study 
because of pre-existing morbidity.
Our analysis lacks measures of iron overload. Serum 
ferritin concentrations are reportedly increased in 80% 
of men (>300 µg/L) and 50% of women (>200 µg/L) with 
p.C282Y homozygosity.32 In an Australian population 
cohort of median age 65 years, serological evidence of 
iron overload (serum ferritin ≥1000 μg/L, considered 
serious by the original authors) was found in 35% 
of male and 6% of female p.C282Y homozygotes.23 
In a study of genotyped patients in eMERGE clinical 
biobanks across seven US health systems,31 100% of 
the male and 50% of the female p.C282Y homozygotes 
had transferrin saturations above 50%. Higher levels of 
iron deposition with HFE genotypes were also reported 
in preliminary findings from UK Biobank subgroups for 
both liver imaging (with seven of eight studied p.C282Y 
homozygotes having evidence of iron overload33) and 
with HFE genotype for iron deposition in certain brain 
regions.34 Future work including serum iron related 
measures could help identify the factors that influence 
why some p.C282Y homozygotes develop associated 
disease but not others and might also help inform 
translational studies to improve diagnosis.
We have been able to study mainly clinical diagnoses, 
but misdiagnoses of iron related disease have been 
reported—for example, with the iron deposition related 
arthrosis misdiagnosed as osteoarthritis or rheumatoid 
arthritis.35 However, our results for p.C282Y 
homozygote associations with musculoskeletal 
diagnoses36 (including16 17 37 38 arthritis, hip 
replacement, and osteoporosis) are consistent with 
previous reports. As follow-up is currently limited in 
duration and does not include primary care recorded 
diagnoses, our estimates of excess morbidity are likely 
to be conservative.
We have avoided adjustment for commonly 
examined confounders in observational studies, 
such as smoking, diet, or exercise, as the genotypes 
studied are inherited at conception and are not altered 
by later exposure. As p.C282Y homozygote men and 
women had more arthritis at baseline, it would not be 
surprising if they therefore did less physical exercise, 
and adjustment for such downstream effects could 
bias results. Instead we have provided sensitivity 
analyses on alcohol intake, as the main previously 
studied modifying exposure.
Adjustment for multiple statistical testing is 
particularly important when examining many 
statistical associations for unrelated outcomes, and 
with low prior probabilities of associations being 
present. However, our analysis is essentially a 
replication of previous similar studies. The deposition 
of excess iron in hereditary haemochromatosis 
results in widespread damage to parenchymal tissue, 
leading to several different diagnoses through the 
common mechanism of iron accumulation.15 It is also 
established that incidence of haemochromatosis is 
higher in men than in women, and that it increases 
with advancing age. There is extensive evidence 
for associations of the studied comparisons in 
patients with haemochromatosis or with the p.C282Y 
genotype, or both, so prior probabilities were high, 
although unquantified in a large community sample. 
To further deal with multiple testing we selected 
only ascertainable conditions previously linked to 
haemochromatosis, clearly identified the post hoc 
sensitivity analyses, and provided a summary estimate 
of all excess incident diagnoses together. We have also 
reported Benjamini-Hochberg adjusted P values to 
quantify multiple testing adjusted significance: more 
data are needed especially on associations that were 
no longer significant.
Clinical and policy implications
Previous community level studies of people homozygous 
for p.C282Y have suggested low penetrance, with 
Beutler et al10 estimating that less than 1% develop 
“frank clinical haemochromatosis.” In UK Biobank, 
haemochromatosis was eventually diagnosed in 
21.7% of male p.C282Y homozygotes and 9.8% of 
women p.C282Y homozygotes, by end of follow-up. 
These diagnostic rates are comparable to the eMERGE31 
clinical biobank study across seven North American 
medical centres, which found that overall 24.4% of 
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men and 14.0% of women p.C282Y homozygotes 
had a diagnosis of haemochromatosis (n=106, mean 
age of diagnosis 61.5 years). Interestingly, survival 
curves to diagnosis in eMERGE suggested that by age 
90, nearly 50% of the men and approximately 25% of 
the women p.C282Y homozygotes had a diagnosis of 
haemochromatosis. It is clear therefore that clinically 
diagnosed haemochromatosis eventually develops in 
large proportions of p.C282Y homozygotes.
Phlebotomy and other iron reducing interventions 
are effective at improving clinical outcomes5 in 
individuals with high iron levels, especially when 
started before development of the related pathologies: 
after pathologies are established, effectiveness is 
limited, especially for arthrosis. In addition, a recent 
randomised trial39 using erythrocytapheresis in 
p.C282Y homozygotes with moderately increased 
serum ferritin concentrations reported improvements 
in patient reported fatigue, with few adverse events. It 
seems likely that intervention before the development 
of pathologies in p.C282Y homozygotes in the 
community could prevent a substantial burden of 
excess morbidity.
Future work
More work is needed to confirm p.C282Y homozygous 
associations with mortality over longer follow-ups, 
with further elucidation of causes of death. Work 
is also needed to establish whether even greater 
excess morbidity develops at older ages than studied 
here, especially in women, as time since menopause 
increases. Large scale studies of p.C282Y homozygotes 
including direct measures of iron status could also help 
identify additional risk factors and improve prediction 
of outcomes. Further data on morbidity associated 
with the lower risk HFE variants is also needed. 
Further analyses are needed to identify possible 
additional variants contributing to haemochromatosis 
penetrance, and further analysis of statistical co-
localisation could help disentangle shared and 
distinct causal variants for each of the various clinical 
manifestations of haemochromatosis.
More work is needed on whether low density 
lipoprotein cholesterol levels increase after iron 
reduction intervention, and whether the risk of 
coronary artery disease can be kept low with statins 
and other preventive interventions. It might be that 
prevention of coronary artery disease could replace the 
beneficial effect of higher iron levels on coronary artery 
disease outcomes in p.C282Y homozygotes, unmasking 
the full detrimental effects of iron accumulation on 
survival.
Although hereditary haemochromatosis is regarded 
as fitting several criteria for genetic screening,10 
the previously reported low clinical penetrance in 
community p.C282Y carriers did not justify screening 
beyond close relatives. In the light of the accumulating 
evidence that penetrance to clinically diagnosed 
morbidity in p.C282Y homozygotes is not uncommon 
and that many cases are missed or diagnosed only 
after substantial morbidity has developed, more work 
is needed to evaluate the various possible approaches 
to improve prevention and early case ascertainment. 
Issues to evaluate include the various options for testing 
(eg, with initial serum ferritin or transferrin saturation 
assays, or perhaps through initial genotyping), and the 
different population or patient groups who might be 
targeted.
Conclusions
In the large UK Biobank community sample, HFE 
p.C282Y homozygotes experienced substantial excess 
prevalent and incident clinical morbidity. This excess 
morbidity was most evident in men but was also 
present in women, and it was more common with 
advancing age. As p.C282Y associated iron overload 
is preventable and partly treatable, re-examination of 
the many issues involved in recommending expanded 
early case ascertainment or screening is justified.
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